Notícias e Atividades da NodThera

Veja o organograma con seus 16 executivos principais

Biografias mais buscadas da NodThera

• Geoff Mcdonough, Chief Executive Officer and Director
• Alex Pasteur, Director
• Jim Trenkle, Director

Recentes movimentos de executivos em NodThera

• Geoff Mcdonough antes Independent Director, foi promovido a Chief Executive Officer and Director  (Notícia publicada em 7 de fevereiro de 2026).
• Geoff Mcdonough, ingressou na Companhia como Independent Director  (Notícia publicada em 18 de dezembro de 2025).
• Chris Guiffre, ingressou na Companhia como Chief Financial Officer  (Notícia publicada em 29 de outubro de 2025).

Clique aqui para ver outras movimentos em NodThera

Criar um alerta
para seguir os movimentos de executivos da NodThera.

NodThera possui 2.429 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado em 15 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Patrick Enright - Director da CuraSen Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de NodThera

• NodThera Announces the Publication and Presentation of Cardiometabolic Clinical Data Supporting the Potential of Ruvonoflast to Treat Inflammation at the Source - Nodthera
• NodThera Announces Late-Breaking Oral Presentation at the 94th EAS Congress - Nodthera
• NodThera to Participate in April Investor Conferences - Nodthera
• NodThera to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Nodthera
• NodThera Announces Appointment of Chris Guiffre, J.D., M.B.A., as Chief Financial Officer - Nodthera
• NodThera Announces First Patients Dosed in RESOLVE-2 Clinical Trial Evaluating Oral NT-0796 in Combination with a GLP-1 Receptor Agonist - Nodthera
• NodThera Announces Appointment of Elisabeth Björk as Board Member - Nodthera
• NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 - Nodthera
• NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer - Nodthera
• NodThera Demonstrates Reversal of Neuroinflammation and Inflammation in Parkinson’s Disease with Oral NLRP3 Inhibitor - Nodthera
• View more press releases Close

Redes sociais sobre NodThera

• NodThera na Wikipedia, Google News e Yahoo Finance
• NodThera na LinkedIn, X (Twitter) e YouTube